Minimal/Measurable Residual Disease (MRD) Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptorwmm2023-04-10T20:24:04-07:00March 2nd, 2023|Read more
Comparing Data Generated Using Multiparametric Flow Cytometry, Capillary Electrophoresis, and Next-Generation Sequencing in a Cohort of B-Cell Lymphoproliferative Disorder Sampleswmm2022-12-29T21:22:21-08:00November 15th, 2022|Read more
LymphoTrack Is Equally Sensitive as PCR GeneScan and Sanger Sequencing for Detection of Clonal Rearrangements in ALL Patientswmm2022-12-29T21:19:31-08:00June 4th, 2022|Read more
Immunoglobulin Heavy Chain High-Throughput Sequencing in Pediatric B-Precursor Acute Lymphoblastic Leukemia: Is the Clonality of the Disease at Diagnosis Related to Its Prognosis?wmm2023-01-08T18:20:36-08:00May 30th, 2022|Read more
Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myelomaInvivoscribe Marketing2022-09-07T22:22:23-07:00May 3rd, 2022|Read more
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AMLInvivoscribe Marketing2022-08-16T20:08:13-07:00August 16th, 2022|Read more
Hitachi High-Tech and Invivoscribe partner to advance molecular diagnostics and precision medicinewmm2022-05-09T17:27:05-07:00May 9th, 2022|Read more
Roswell Park Comprehensive Cancer Center Licenses Invivoscribe’s LymphoTrack Software for Plug and Play Pipeline UseInvivoscribe Marketing2021-09-02T16:53:40-07:00September 2nd, 2021|Read more
Invivoscribe Announces Key Submission in the EU, Expanded Presence and Activity in ChinaInvivoscribe Marketing2021-07-22T17:27:56-07:00July 22nd, 2021|Read more
Invivoscribe Launches Grant Program to Support Novel Applications for Sequence-Based Analyses of the Immune Systemwmm2021-06-24T18:20:34-07:00June 24th, 2021|Read more